Localization of the activity of arylsulphatases A and B in the rat salivary glands.

L. Vitaioli,A. Bondi,G. Menghi,G. Materazzi

DOI: https://doi.org/10.1016/S0065-1281(81)80011-6

IF: 2.147

Acta Histochemica

Abstract:

What problem does this paper attempt to address?

Performance of preferentially expressed antigen in melanoma (PRAME) immunohistochemistry for metastatic melanoma in cytology specimens

Mohammed Saad,Richard Cantley,Wei Hao,Zixi Wang,Dafydd Thomas,Liron Pantanowitz,Xiaobing Jin

DOI: https://doi.org/10.1002/dc.25313

2024-04-03

Diagnostic Cytopathology

Abstract:Background Preferentially expressed antigen in melanoma (PRAME) has been introduced as a new melanoma marker and potential target for immunotherapy. While PRAME immunohistochemistry (IHC) is well documented in surgical pathology, similar data in cytology are limited. Metastatic melanoma is frequently diagnosed via cytology samples in which IHC plays an important role. We aimed to accordingly evaluate the performance of PRAME IHC in diagnosing metastatic melanoma in cytology samples relative to other commonly used melanoma markers. Materials and Methods The study included 156 archival cytology cases, of which 93 were melanoma cases and 63 nonmelanoma cases (controls). All cases underwent PRAME IHC staining on cell blocks. Nuclear staining of PRAME was evaluated using a quantitative and qualitative scale. Other melanocytic IHC stain results (SOX10, S‐100, Melan‐A, and HMB45) were also documented. Results PRAME was detected in tumor cells in 86% of melanoma cases, which was significantly lower than SOX10 (100%) (p

pathology,medical laboratory technology
PRAME Expression Is a Useful Tool in the Diagnosis of Primary and Metastatic Dedifferentiated and Undifferentiated Melanoma

Jason L Hornick,Jose A Plaza,Thomas Mentzel,Alejandro A Gru,Thomas Brenn

DOI: https://doi.org/10.1097/PAS.0000000000002125

2023-12-01

Abstract:Although mostly recognized in the metastatic setting dedifferentiated and undifferentiated melanomas are increasingly recognized as cutaneous and, less commonly, mucosal primary tumors. Their diagnosis is challenging and dependent on sampling and recognition of a conventional melanoma precursor and/or detection of a mutation in a conventional melanoma driver gene. PRAME immunohistochemistry has recently become an important ancillary tool in the separation of melanoma from benign nevi, but no comprehensive studies exist regarding its value in the detection of dedifferentiated and undifferentiated melanomas and their separation from atypical fibroxanthoma and pleomorphic dermal sarcoma, the main differential diagnoses on sun-damaged skin. After retrieval from archival files, we performed PRAME immunohistochemistry on 11 primary and 10 metastatic dedifferentiated and undifferentiated melanomas, 11 atypical fibroxanthomas, and 10 pleomorphic dermal sarcomas. Nuclear staining was assigned extent (ranging from 0 to 4 and reflecting the percentage of PRAME-positive tumor nuclei) and intensity scores (graded as absent, weak, moderate, and strong, with assigned scores ranging from 0 to 3) with combined scores ranging from 0 to 7. Both primary and metastatic dedifferentiated and undifferentiated melanomas showed strong and diffuse nuclear PRAME staining with median combined scores of 7. Strong and diffuse staining was also seen in all conventional melanoma precursors except for desmoplastic melanoma. In contrast, PRAME staining in atypical fibroxanthoma and pleomorphic dermal sarcoma was patchy and weak with median combined scores of 2. Our data emphasize the diagnostic utility of PRAME staining as a first screening tool in the detection and workup of dedifferentiated and undifferentiated melanomas, both in the primary and metastatic settings. PRAME immunohistochemistry is particularly helpful as it is also positive in tumors without a recognizable conventional melanoma precursor and in those associated with desmoplastic melanomas, where PRAME is typically found to be negative.
PRAME expression in spindle cell melanoma, malignant peripheral nerve sheath tumour, and other cutaneous sarcomatoid neoplasms: a comparative analysis

Steven M Hrycaj,Julianne M Szczepanski,Lili Zhao,Javed Siddiqui,Dafydd G Thomas,David R Lucas,Rajiv M Patel,Paul W Harms,Scott C Bresler,May P Chan

DOI: https://doi.org/10.1111/his.14797

Histopathology

Abstract:Diagnosis of spindle cell/sarcomatoid melanoma may be challenging due to frequent loss of expression of melanocytic marker(s) and histomorphologic resemblance to various mesenchymal tumours, particularly malignant peripheral nerve sheath tumour (MPNST). Overexpression of PReferentially expressed Antigen in MElanoma (PRAME) supports a diagnosis of melanoma when evaluating challenging melanocytic tumours. PRAME expression in MPNST and other cutaneous sarcomatoid neoplasms, however, has not been well characterised. We aimed to determine the utility of PRAME immunostain in distinguishing spindle cell melanoma from MPNST and other sarcomatoid mimics. PRAME expression was scored by extent (0 to 4+) and intensity (0 to 3) of staining. A strong positive correlation was observed between the extent and intensity scores (r = 0.84). An extent score of 4+, defined by staining in 76-100% of tumour cells, was seen in 56% (23/41) of spindle cell melanomas, 18% (7/38) of MPNSTs, 15% (4/27) of cutaneous sarcomatoid squamous cell carcinomas (SCCs), 33% (5/15) of poorly differentiated cutaneous angiosarcomas, 12% (4/33) of atypical fibroxanthomas (AFXs), 4% (1/25) of pleomorphic dermal sarcomas (PDSs), and none (0/16) of the high-grade cutaneous leiomyosarcomas. A significant difference was found between spindle cell melanoma and all other examined sarcomatoid neoplasms except angiosarcoma. While diffuse (and often strong) PRAME expression is more frequently observed in spindle cell melanoma than MPNST, sarcomatoid SCC, AFX, PDS, and high-grade leiomyosarcoma, its limited sensitivity and specificity caution against its use as a standalone diagnostic marker. PRAME may complement other epigenetic or lineage-specific markers and should only be used as part of an immunohistochemical panel when evaluating these sarcomatoid neoplasms.
Analysis of PRAME immunocytochemistry in 109 acral malignant melanoma in situ

Qiu-ju Miao,Jie Zang,Xue-Bao Shao,Jian-fang Sun,Yan-Ping Chen,Hao Chen

DOI: https://doi.org/10.1136/jcp-2022-208697

2023-03-07

Journal of Clinical Pathology

Abstract:Aims Preferentially expressed antigen in melanoma (PRAME) recently is a reliable immunohistochemistry (IHC) marker for distinguishing melanoma from other lesions. However, there are few articles focused on PRAME use in acral malignant melanoma, the most common type in Asians. This study investigated PRAME IHC expression in a large series of acral malignant melanoma in situ to add to the body of clinical knowledge. Methods PRAME IHC was performed in unequivocal cases of primary acral lentiginous melanoma in situ (ALMIS), subungual melanoma in situ (SMIS) and acral recurrent nevi as the control. PRAME tumour cell percentage positivity and intensity were expressed as categorised in a cumulative score by adding the quartile of positive tumour cells to intensity labelling. The final IHC expression was interpreted as negative (0–1), weak (2–3), moderate (4–5) or strong (6–7). Results In 91 ALMIS patients, 32 cases (35.16%) were strong, 37 (40.66%) were moderate and 22 (24.18%) were weak. In 18 SMIS patients, strong positivity of PRAME was observed in 4 (22.22%) cases, moderate in 10 (55.56%) and weak in the remaining 4 (22.22%). No melanoma sample was negative for PRAME. By comparison, only 2 of the 40 acral recurrent nevi cases were positive. Conclusions Our study supports the ancillary value of PRAME for diagnosing ALMIS and SMIS with high sensitivity and specificity.

pathology
Preferentially Expressed Antigen in Melanoma Immunohistochemistry As an Adjunct for Differential Diagnosis in Acral Lentiginous Melanoma and Acral Nevi

Jue Hu,Xu Cai,Jiao-Jie Lv,Xiao-Chun Wan,Xue-Ying Zeng,Ming-Li Feng,Bo Dai,Yun-Yi Kong

DOI: https://doi.org/10.1016/j.humpath.2021.11.002

IF: 3.526

2022-01-01

Human Pathology

Abstract:Preferentially expressed antigen in melanoma (PRAME) has shown promising utility in distinguishing benign melanocytic lesions from melanomas, but knowledge of its expression pattern in acral lentiginous melanoma (ALM) and acral nevi (ANs) is limited. Immunohistochemical expression of PRAME was examined in 75 ALMs and 34 ANs. The clinical and histopathologic characteristics of patients with ALM were collected. PRAME was immunoreactive in 89.3% (67/75) of ALMs, but entirely negative in 94.1% (32/34) of ANs. When staining at least 50% of lesional melanocytes was determined as positivity, the sensitivity and specificity of PRAME for distinguishing ALM from ANs were 69.3% and 100%, respectively. Seventy-one cases of ALMs had tumor cells in the epidermis; 71.8% (51/71) of them showed positive for PRAME. By contrast, 61 ALMs had tumor cells in the dermis; 65.6% (40/61) exhibited positive expression. Twenty-nine of 39 (74.4%) epithelioid cell ALMs were observed to be positive for PRAME. By comparison, 63.8% (23/36) of ALMs with spindle tumor cells were positive for PRAME. However, PRAME positive expression was not associated with any clinical and histopathologic characteristics of patients with ALM, including Breslow thickness, ulcer, cytomorphology, lymph node metastasis, or tumor-infiltrated lymphocytes (TILs). Nevertheless, we observed that 82.6% (19/23) of ALMs with lymph node involvement at diagnosis expressed PRAME, compared with 57.6% (20/35) of those without. In summary, PRAME immunohistochemistry can serve as a helpful adjunct in the differential diagnosis of ALMs and ANs with good sensitivity and high specificity. Additionally, PRAME tends to have a higher positive rate in epidermal melanocytes than in the dermis and is inclined to express in epithelioid cells than in spindle cells of ALMs.
Differential expression of preferentially expressed antigen in melanoma (PRAME) in testicular germ cell tumors - A comparative study with SOX17

Yan Zhou,Aimi Rothrock,Paari Murugan,Faqian Li,Lihong Bu

DOI: https://doi.org/10.1016/j.yexmp.2022.104761

Abstract:The accurate identification of different components in testicular germ cell tumors (GCT) is essential for tailoring treatment and informing the clinical prognosis. PRAME (preferentially expressed antigen in melanoma), a member in the family of cancer testis antigens, plays critical roles in regulating pluripotency and suppressing somatic/germ cell differentiation in seminomas (SEM). To investigate the potential diagnostic value of PRAME in testicular GCT, here we comparatively examined the expression patterns of PRAME and SOX17 by immunohistochemistry in both pure and mixed GCT. Tissue microarrays constructed from 66 pure or mixed GCT were examined, including 25 seminomas (13 pure and 12 mixed), 35 embryonal carcinomas (EC; 7 pure and 28 mixed), 23 teratomas (TER; 10 pure and 13 mixed), 15 yolk sac tumors (YST; 1 pure and 14 mixed), and 5 choriocarcinomas (CC; 1 pure and 4 mixed), with 11 germ cell neoplasia in situ (GCNIS) and 6 normal testicular tissue as controls. The expression levels of PRAME or SOX17 were evaluated by a scoring system counting for intensity and extent of staining. PRAME nuclear expression was present in 92% (23/25) of SEM, including all 13 pure SEM, and 10 out of 12 seminomatous component of mixed GCT. In contrast, all EC and TER were completely negative for PRAME, and focal expression was demonstrated in 33.3% of YST and 20% of CC. As for SOX17, 96% of SEM and 73% of YST stained positively, whereas EC and CC were negative. Focal nuclear positivity was identified in the epithelial cell component of 17.4% (4/23) of TER. We found the sensitivity of PRAME to detect SEM to be comparable to SOX17, although SOX17 staining is more diffuse and stronger in the majority of cases. The specificity of PRAME for SEM appeared to be superior to that of SOX17 (92% versus 81%). In conclusion, PRAME is preferentially expressed in SEM or within the seminomatous component of mixed GCT with only focal variable expression in YST and CC, but shows no expression in EC and TER. These findings suggest that PRAME can be explored as a diagnostic marker for SEM.
Comparison of S100A8 and PRAME as biomarkers for distinguishing melanoma from melanocytic nevus: a case-control analysis

Josephine Hai,Summer N Meyer,Samantha L Wong,Yueju Li,Elanee Simmons,Diana Miglioretti,Maxwell A Fung,Maija Kiuru,Maxwell Fung

DOI: https://doi.org/10.1093/ced/llae005

2024-02-02

Clinical and Experimental Dermatology

Abstract:Abstract Background S100A8 is a melanoma biomarker expressed in the melanoma-associated epidermal keratinocytes, but its diagnostic utility has not been compared to other biomarkers, including PRAME. Objectives This case-control study compares the utility of S100A8 and PRAME immunohistochemistry in the differential diagnosis of melanoma and nevi. Methods A previously described cohort of 209 melanomas and nevi dual-immunostained for S100A8 and PRAME were included. For S100A8, previously reported scores indicating the proportion of tumor-associated epidermis stained (0=indeterminate; 1= 0-4%; 2= 5-25%; 3= 26-50%; 4= 51-75%; 5> 75%) were utilized. PRAME IHC was reviewed by at least two reviewers and a consensus score assigned, with score indicating the proportion of tumor stained (0=indeterminate; 1= 0%; 2= 1-50%; 3> 50%). A positive test was defined as >50% staining. Results The area under the receiver operating characteristic curves for S100A8 (0.833) and PRAME (0.874) were not significantly different from each other (p=0.22). The diagnostic sensitivity and specificity (95% CI) was 42.4% (32.55%-52.77%) and 98.2% (93.6%-99.8%) for S100A8, and 79.8% (70.5%-87.2%) and 87.3% (79.6%-92.9%) for PRAME, respectively. A combined test requiring both S100A8 and PRAME IHC positivity had a sensitivity of 39.4% (29.7%-49.7%) and specificity of 99.1% (95.0%-100.0%). Conclusion S100A8 and PRAME have utility in the diagnostic workup of melanoma, with S100A8 being more specific and PRAME being more sensitive when using this threshold. Our findings suggest that these two immunohistochemical markers may favorably complement one another to improve the detection of melanoma.

dermatology
A Comparison of Preferentially Expressed Antigen in Melanoma Immunohistochemistry and Diagnostic Gene Expression-Profiling Assay in Challenging Melanocytic Proliferations

Austin C. Casillas,Aaron Muhlbauer,Victor A. Barragan,Itisha Jefferson,Jodi J. Speiser

DOI: https://doi.org/10.1097/dad.0000000000002501

2024-02-16

American Journal of Dermatopathology

Abstract:Most melanocytic tumors are classified as benign or malignant based on clinical morphology, histology, and immunohistochemical (IHC) analysis. A subset of more challenging cases with ambiguous features may require further evaluation with established ancillary diagnostic molecular studies, including fluorescence in situ hybridization and/or single nucleotide polymorphism array, to increase diagnostic certainty. More recently, a diagnostic gene expression-profiling (GEP) assay and an IHC stain for the detection of PRAME (PReferentially expressed Antigen in MElanoma) have been developed. The use of PRAME IHC has been validated in cases of unequivocal and ambiguous melanocytic proliferations via comparing results with fluorescence in situ hybridization and/or single nucleotide polymorphism array. A study comparing performance metrics of PRAME IHC and diagnostic GEP has not been previously published. Herein, we evaluated the use of PRAME IHC in 55 melanocytic tumors with challenging histomorphology by comparing the results with diagnostic GEP and final histomorphologic diagnosis. Intertest agreement occurred in 88% of cases. PRAME IHC supported the final diagnosis in 89% of cases with a sensitivity of 79%, specificity of 95%, and positive predictive value of 88.2%. GEP agreed with the final diagnosis in 88% of cases with a sensitivity of 65%, 97% specificity, and positively predicted melanoma in 91.7% of cases. Because the results of this study align with past publications evaluating the performance metrics of PRAME IHC, showing it to be as sensitive as and more cost effective than all other ancillary molecular tests, we propose the use of PRAME IHC as the optimal first-line diagnostic tool for ambiguous melanocytic proliferations.

dermatology
PRAME Expression in Challenging Dermal Melanocytic Neoplasms and Soft Tissue Tumors With Melanocytic Differentiation

Nicholas Kline,Tyler D Menge,Steven M Hrycaj,Aleodor A Andea,Rajiv M Patel,Paul W Harms,May P Chan,Scott C Bresler

DOI: https://doi.org/10.1097/DAD.0000000000002128

2022-06-01

Abstract:Preferentially expressed antigen in melanoma (PRAME) is an immunohistochemical biomarker that is diffusely expressed in most cutaneous melanomas and is negative in most benign nevi. Histologically challenging dermal melanocytic neoplasms, such as cellular blue nevi (CBN) and deep penetrating nevi (DPN), and soft tissue tumors with melanocytic differentiation, such as clear cell sarcoma and perivascular epithelioid cell tumor, may resemble primary or metastatic melanoma. PRAME immunohistochemistry (IHC) was applied to archived formalin-fixed, paraffin-embedded specimens of various dermal melanocytic neoplasms and soft tissue neoplasms with melanocytic differentiation. Staining was graded based on the percentage of melanocytes labeled (0-4+ as previously reported). The gold standard was final pathologic diagnosis using histologic, immunophenotypic, and in some cases molecular findings. Fifty-four cases were evaluated. 62.5% (5/8) of blue nevus-like melanomas and 50% (1/2) of DPN-like melanomas were PRAME positive (4+). Of the other tumors, 100% (20/20) of CBN (including 1 atypical CBN with borderline features); 100% (12/12) of DPN, combined DPN, or borderline DPN; 88.9% (8/9) of perivascular epithelioid cell tumors; and 100% (3/3) of clear cell sarcoma were PRAME negative (0-2+). Within the borderline categories specifically, all 8 tumors (1 borderline CBN and 7 borderline DPN) showed low (0-2+) PRAME expression. Overall, the sensitivity for melanoma in this context was 60%, with a specificity of 97.7%. Although our sample size is limited, the results suggest that IHC staining for PRAME may be useful in supporting a diagnosis of melanoma in the setting of challenging dermal melanocytic neoplasms and other epithelioid neoplasms with melanocytic differentiation. However, PRAME IHC lacks sensitivity in this context.
Progesterone Receptor and Progesterone Receptor B Isoform Expression and Their Clinical Significance in Endometrial Adenocarcinoma

张俊梅,周蓉,杨大同,魏丽惠,屠铮,虞有智,张宏伟

DOI: https://doi.org/10.3969/j.issn.1672-1861.2002.02.010

2002-01-01

Abstract:Objective To study the progesterone receptor (PR) and progesterone receptor B ( PR B) expression and their clinical significance in endometrial adenocarcinoma. Methods The specimens of 30 patients with endometrial adenocarcino-ma were used in this study. All the specimens were formalin - fixed, paraffin - embedded, cut and mounted onto the slides. Sections were stained for PR and PR B by the immunohistochemistry technique.Ten specimens of normal proliferative phase endometri-um were also detected as control group. Results PR and PR B were nuclei receptors. Positive expression of PR and PR B were in 93.33% and 50% of the cancer specimens respectively. All specimens of control group were positive staining of the PR and PR B. The expression of PR had no relations with the differentiation and clinical stage of the cancer. There were more well - differentiated tumors in PR B positive specimens than that in PR B negative specimens, but the expression of PR B had no relations with the clinical stage of the cancer. Conclusions PR and PR B had different expression in endometrial adenocarcinoma. The expression rate of PR B had positive correlation with the differentiation of the cancer. To detect the expression of PR and PR B may have some roles in the guidance of the endocrinotherapy and prognosis of the endometrial adenocarcinoma.
Clinical implication of PRAME immunohistochemistry in differentiating melanoma in situ and dysplastic nevus in non‐acral nevus‐associated melanoma in situ: An institutional experience and meta‐analysis

Chau M. Bui,Huy Gia Vuong,Minh‐Khang Le,Josephine D'Angelo,Kathleen Mannava,Bruce R. Smoller

DOI: https://doi.org/10.1111/cup.14671

2024-06-23

Journal of Cutaneous Pathology

Abstract:Introduction PReferentially expressed Antigen in MElanoma (PRAME) has shown utility in differentiating benign from malignant melanocytic neoplasms. In this study, we investigated the clinical significance of PRAME expression in dysplastic nevi (DN) and nevus‐associated melanoma in situ (MIS). Methods We included 172 DN and 38 nevus‐associated MIS from our institutional archive. PRAME positive expression was defined as nuclear staining in at least 75% of melanocytes. In addition, relevant studies from PubMed and Web of Science were incorporated into a meta‐analysis using the random‐effects model to assess PRAME expression in MIS and DN. Results Our institutional data revealed that 71.1% of nevus‐associated MIS cases exhibited positive PRAME expression in the MIS components, whereas all DN components were negative for PRAME. 5.7% of cases diagnosed as DN in our cohort demonstrated diffuse positivity for PRAME. Notably, MIS associated with DN displaying epidermal and dermal components displayed a higher likelihood of PRAME positivity compared to those arising on a background of DN with solely epidermal (junctional) components (84% vs. 46%, p = 0.024). The meta‐analysis indicated that the pooled PRAME positivity in MIS and DN was 54.5% and 1.9%, respectively. Conclusion PRAME is a valuable immunohistochemical marker for differentiating MIS from DN, particularly in the context of nevus‐associated MIS.

dermatology,pathology
PRAME expression and its prognostic significance in invasive breast carcinoma

Lea Korša,Martina Abramović,Lucija Kovačević,Milan Milošević,Paula Podolski,Maja Prutki,Zlatko Marušić

DOI: https://doi.org/10.1016/j.prp.2024.155096

IF: 3.309

2024-02-01

Pathology - Research and Practice

Abstract:OBJECTIVES: PRAME (PReferentially expressed Antigen in MElanoma) is a carcinoma testis antigen expressed in numerous tumour types. The aim of this study was to assess PRAME expression in different surrogate subtypes of breast carcinoma and its correlation with other prognostic factors.MATERIAL AND METHODS: A total of 220 cases of invasive breast carcinoma were selected and categorized according to ER, PgR, HER2 status, and Ki67 proliferation index in luminal A like, luminal B HER2+ like, luminal B HER2- negative like, HER2 positive like and triple-negative or basal-like. All cases were examined for PRAME expression by immunohistochemistry (IHC).RESULTS: A PRAME-high profile was detected in 53 (24,1 %) of all examined breast carcinoma samples. A significantly higher expression of PRAME was detected in HER2-positive carcinomas (50 %) and TN breast carcinomas (40,54 %) compared to ER-positive (luminal-like) subtype of breast carcinomas (3,38 % luminal A and 15,38 % luminal B). Percentage of PRAME positive tumour cells showed positive correlation with tumor size, Ki67 proliferation index, HER2 status, nuclear grade, TILs and presence of metastasis, and negative correlation with ER status and disease-free survival (DFS).CONCLUSION: Our study showed that HER2 positive and TN breast carcinomas more commonly express PRAME than ER positive carcinomas and that PRAME expression shows positive correlation with certain prognostic factors, however PRAME wasn't revealed as an independent prognostic factor in our study. The importance of PRAME expression in breast carcinoma lies in its potential use as an immunotherapeutic target, particularly in patients with limited therapeutic options.

pathology
Evaluation of PRAME immunohistochemistry in cutaneous vascular neoplasms reveals frequent expression in primary and post‐irradiation cutaneous angiosarcomas

Andrea Krajisnik,Neda Rezaee,Eleanor R. Duncan,Bonnie L. Balzer,Wonwoo Shon

DOI: https://doi.org/10.1111/cup.14707

2024-08-19

Journal of Cutaneous Pathology

Abstract:Background Preferentially expressed antigen in melanoma (PRAME) has been extensively studied in cutaneous melanocytic tumors and has proven valuable as a diagnostic adjunct in routine dermatopathology practice. However, its expression in cutaneous vascular neoplasms, particularly angiosarcomas (AS), remains largely unexplored. Methods To further explore PRAME expression in cutaneous AS, 18 cases of post‐irradiation and 13 cases of primary cutaneous AS were evaluated for PRAME. For comparison, sections from 11 deep soft tissue/visceral AS, 10 Kaposi sarcomas, 8 microvenular hemangiomas, 7 infantile hemangiomas, 8 atypical vascular lesions, 6 epithelioid hemangioendotheliomas, 6 pyogenic granulomas, 6 papillary endothelial hyperplasias, 6 epithelioid hemangiomas, 3 capillovenous malformations, 3 hobnail hemangiomas, 2 spindle cell hemangiomas, 2 pseudomyogenic hemangioendotheliomas, and 2 composite hemangioendotheliomas were also retrieved. Results Overall, 22 of 31 (70.9%; 12 post‐irradiation and 10 primary) cutaneous AS were positive for PRAME. In contrast, only 1 of 11 (9.1%) deep soft tissue/visceral AS showed diffuse and strong PRAME nuclear staining. All other tumor types were negative for PRAME, except for 5 of 7 (71.4%) infantile hemangiomas, which demonstrated rare (<5%; four cases) and 1+ (5–25%; one case) nuclear staining. Conclusions In this study, we have demonstrated frequent nuclear PRAME expression in cutaneous AS. PRAME immunohistochemistry may serve as a valuable additional marker in selected clinical settings.

dermatology,pathology
Endocervical adenocarcinomas classified by International Endocervical Adenocarcinoma Criteria and Classification: a clinicopathological and prognostic analysis of 286 cases

邵颖,吕卫国,石海燕,刘琴,吕炳建

DOI: https://doi.org/10.3760/cma.j.cn112151-20210524-00374

2021-01-01

Abstract: To investigate the clinicopathological and prognostic significance of International Endocervical Adenocarcinoma Criteria and Classification (IECC) in classifying endocervical adenocarcinomas among Chinese women. A total of 286 endocervical adenocarcinomas diagnosed from January 2013 to December 2019 at the Women's Hospital, Zhejiang University School of Medicine were identified and included. The cases were reviewed and reclassified based on IECC. The histological types were correlated with p16 immunostaining, human papilloma virus (HPV) mRNA status, the clinicopathological parameters including the International Federation of Gynecologic Oncology (FIGO) stage, and clinical follow-up data. The patients aged from 19 to 77 (median 47) years. There were 223 patients at FIGO stage Ⅰ, 22 at stage Ⅱ, 38 at stage Ⅲ and 3 at stage Ⅳ. The IECC types included 213 (74.5%) HPV-related adenocarcinomas (HPVA), 60 (21%) non-HPV-related adenocarcinomas (NHPVA), and 13 (4.5%) adenocarcinomas, no other specified (NOS). The major histological subtypes in HPVA and NHPVA were common type (=156, 54.5%) and gastric type (GAC, =46, 15.9%), respectively. The p16 positive rates in HPVA, NHPVA and adenocarcinoma, NOS were 92% (173/188), 26.6% (17/64) and 61.5% (8/13), respectively, and those of HPV mRNA hybridization in situ were 89.4% (144/161), 0/18 and 7/13, respectively. Compared to HPVA, NHPVA was more frequently associated with older age, FIGO stage Ⅱ-Ⅳ, neural involvement, lymphovascular invasion and aberrant p53 expression (<0.05). Univariate survival analysis showed that age (>47 years), NHPVA, GAC, FIGO stage Ⅱ-Ⅳ, neural involvement, lymphovascular invasion and aberrant p53 expression were indicators for a poorer overall survival and tumor recurrence (<0.05). Mucinous HPVA showed worse clinical outcomes compared to usual-type HPVA (<0.01). Multivariate survival analysis demonstrated that FIGO stage Ⅱ-Ⅳ, NHPVA and aberrant p53 expression were independent indicators for poor overall survival while FIGO stage Ⅱ-Ⅳ and GAC were independently associated with tumor recurrence (<0.05). The two broad IECC categories, HPVA and NHPVA, not only provide morphological links to the etiology (HPV infection), but also have significant clinicopathological and prognostic relevance.
Relationships Between the Molecular Biomarkers and the Clinicopathologic Features and Prognosis in Endometrial Carcinoma

Yuan-yang Yao,Wen-zhan Xu,Yue Wang,Dan-hua Shen,Jian-liu Wang,Li-hui Wei

DOI: https://doi.org/10.3969/j.issn.1671-167x.2011.05.022

2011-01-01

Abstract:OBJECTIVE:To explore the relationships between the expressions of estrogen receptor (ER), progestin receptor (PR), phosphatase and tension homology deleted on chromosome ten (PTEN), p53, Ki-67 and the clinicopathologic features and prognosis in endometrial carcinoma.METHODS:The data of clinical characteristics, pathological types, histological grades, follow-ups and the expressions of molecular markers detected by immunohistochemistry, and collected from 200 patients with primary endometrial carcinoma, were analyzed.RESULTS:(1) In the cases of endometrial carcinoma, the expression rates of ER, PR, PTEN, p53 were 86.5%, 85.5%, 82.1%, and 49.2%, respectively. The expression level of Ki-67 in the tumor tissues was 46.9% ± 24.7%. (2) A negative correlation was observed between the gravidity and the expression of PR (r=-0.191, P=0.007). On the other hand, age and parturition time were in positive correlation with the expression of p53 (r=0.184, P=0.041; r=0.255, P=0.004). (3) The expression rates of ER, PR and p53 in the endometrioid carcinoma exhibited significant differences comparing with other types (P<0.01). (4) A negative correlation was found between the expression of ER and the FIGO staging (r=-0.176, P=0.013). The positive rate of ER in the cases with Stage I was higher than that in cases with Stage II and above (P=0.015). (5) A negative correlation was found between the histological grade and the expressions of ER and PR (r=-0.217, P=0.002; r= -0.317, P=0.000), however, a positive correlation was detected between the grade with the expressions of p53 and Ki-67 (r=0.327, P=0.000; r=0.465, P=0.000). Compared with the grade 3 tumors, the other grades exhibited significant different expression levels of ER, PR, p53, and Ki-67 (P<0.01). (6) A negative correlation was observed between the depth of myometrial invasion and the positive rate of ER (r=-0.142, P=0.047). There were statistically significant different expression rates of ER and PR between the cases whether the cancer invaded the deep myometrium or not (P<0.05). (7) Multivariate survival analysis showed that patients with PR (+) had longer overall survival than those with PR (-) (P=0.011).CONCLUSION:The immunohistochemical study of endometrium samples obtained from dilatation and curettage of uterine will be beneficial to the understanding of the clinicopathologic features of the endometrial carcinoma before the operation. The value of estimating the prognosis using the expressions of ER, PTEN, p53 and Ki-67 was negative, except for the expression of PR.
Distinctive Features of Immunostaining and Mutational Load in Primary Pulmonary Enteric Adenocarcinoma: Implications for Differential Diagnosis and Immunotherapy

Ming Chen,Pu Liu,Feifei Yan,Suzhen Xu,Qi Jiang,Jingying Pan,Mengye He,Peng Shen

DOI: https://doi.org/10.1186/s12967-018-1449-z

IF: 8.44

2018-01-01

Journal of Translational Medicine

Abstract:Background Primary pulmonary enteric adenocarcinoma (PEAC) is an extremely rare variant of invasive lung cancer. It is highly heterogeneous while shares some common morphologic and immunohistochemical features with usual pulmonary adenocarcinoma (PAC) and colorectal adenocarcinoma (CRAC), making the differential diagnosis difficult. At present there are only limited studies about distinctive features of primary PEAC and the results are often inconsistent. Methods We retrospectively analyzed total 129 primary PEACs and 50 CRACs that were published since 1991 or diagnosed in our centre. Among them eight typical samples of primary PEACs and usual PACs were detected by targeted exome sequencing. Results The combination of CK7 + /CDX2 + acquires high sensitivity (71.3%) and specificity (82%) in differential diagnosis of PEACs from CRAC. The primary PEACs harbor a high incidence of KRAS mutation but almost absent of EGFR mutation. Moreover, compared with usual PACs, the primary PEACs have higher nonsynonymous tumor mutation burden and more frequent MMR mutation. Conclusions The combination of CK7 + /CDX2 + immunostaining and the distinctive genetic signatures, including low incidence of sensitivity genes mutations and high tumor mutation burden, is an important supplementary to the clinical differential diagnosis of primary PEACs. Our findings thus have significant implications for development of individualized treatment strategy in these patients.
The synergistic effect of conventional and sustained delivery of antioxidants on LNCaP prostate cancer cell line.

L. Richards,H. Benghuzzi,M. Tucci,J. Hughes

Biomedical Sciences Instrumentation

Abstract:Studies have been limited involving antioxidants as a mode of treatment for prostate cancer. The goal of this study was to develop alternative treatment and prevention for the invasive behavior of prostatic mutations by exploring the synergistic effects of several commercially available antioxidants. The specific aims were to examine the viability, proliferation, and morphology of human prostate cells in culture upon treatment of low and high doses of vitamin E, selenium, and lycopene alone or in combination. In phase I, groups were treated with physiological doses of the experimental agents. In phase II, the same groups were treated in combination to observe any synergistic effect. Upon treatment with selenium, lycopene, and vitamin E, vitamin E treated groups demonstrated the greatest effect on most assays in the study. Data obtained from this study did not demonstrate that the antioxidants would eradicate LNCaP prostatic carcinoma cells; however, the suppression of the metabolic pathways, cellular damage, and lowered prostatic specific antigen was observed.
PRAME Is an Effective Tool for the Diagnosis of Nevus-Associated Cutaneous Melanoma

Andrea Ronchi,Gerardo Cazzato,Giuseppe Ingravallo,Giuseppe D'Abbronzo,Giuseppe Argenziano,Elvira Moscarella,Gabriella Brancaccio,Renato Franco

DOI: https://doi.org/10.3390/cancers16020278

2024-01-10

Cancers

Abstract:(1) Background: Nevus-associated cutaneous melanoma (CM) is relatively common in the clinical practice of dermatopathologists. The correct diagnosis and staging of nevus-associated cutaneous melanoma (CM) mainly relies on the correct discrimination between benign and malignant cells. Recently, PRAME has emerged as a promising immunohistochemical marker of malignant melanocytes. (2) Methods: PRAME immunohistochemistry (IHC) was performed in 69 cases of nevus-associated CMs. Its expression was evaluated using a score ranging from 0 to 4+ based on the percentage of melanocytic cells with a nuclear expression. PRAME IHC sensitivity, specificity, positive predictive values, and negative predictive values were assessed. Furthermore, the agreement between morphological data and PRAME expression was evaluated for the diagnosis of melanoma components and nevus components. (3) Results: PRAME IHC showed a sensitivity of 59%, a specificity of 100%, a positive predictive value of 100%, and a negative predictive value of 71%. The diagnostic agreement between morphology and PRAME IHC was fair (Cohen's Kappa: 0.3); the diagnostic agreement regarding the benign nevus components associated with CM was perfect (Cohen's Kappa: 1.0). PRAME was significantly more expressed in thick invasive CMs than in thin cases (p = 0.02). (4) Conclusions: PRAME IHC should be considered for the diagnostic evaluation of nevus-associated CM and is most useful in cases of thick melanomas. Pathologists should carefully consider that a PRAME-positive cellular population within the context of a nevus could indicate a CM associated with the nevus. A negative result does not rule out this possibility.

oncology
PRAME immunohistochemistry in soft tissue tumors and mimics: a study of 350 cases highlighting its imperfect specificity but potentially useful diagnostic applications

Chloé Cammareri,Fanny Beltzung,Michael Michal,Lucile Vanhersecke,Jean-Michel Coindre,Valérie Velasco,François Le Loarer,Béatrice Vergier,Raul Perret

DOI: https://doi.org/10.1007/s00428-023-03606-6

Abstract:Preferentially expressed antigen in melanoma (PRAME) immunohistochemistry is currently used in pathology for the assessment of melanocytic neoplasms; however, knowledge of its expression patterns in soft tissue tumors is limited. PRAME immunohistochemistry (clone QR005) was assessed on whole tissue sections of 350 soft-tissue tumors and mimics (> 50 histotypes). PRAME immunoreactivity was evaluated as follows: 0 "negative" (0% positive cells); 1+ (1-25% positive cells); 2+ (26-50% positive cells); 3+ (51-75% positive cells), and 4+ "diffuse" (> 75% positive cells). PRAME was expressed in 111 lesions (0 benign, 6 intermediate malignancy, and 105 malignant), including fibrosarcomatous dermatofibrosarcoma protuberans (2/4, 0 diffuse), NTRK-rearranged spindle cell neoplasm (2/4, 0 diffuse), atypical fibroxanthoma (1/7, 0 diffuse), Kaposi sarcoma (1/5, 0 diffuse), myxoid liposarcoma (11/11, 9 diffuse), synovial sarcoma (11/11, 6 diffuse), intimal sarcoma (7/7, 5 diffuse), biphenotypic sinonasal sarcoma (3/3, 1 diffuse), angiosarcoma (10/15, 6 diffuse), malignant peripheral nerve sheath tumor (9/12, 4 diffuse), pleomorphic rhabdomyosarcoma (2/3, 2 diffuse), alveolar rhabdomyosarcoma (2/6, 0 diffuse), embryonal rhabdomyosarcoma (7/7, 4 diffuse), undifferentiated pleomorphic sarcoma (2/12, 1 diffuse), leiomyosarcoma (2/15, 1 diffuse), clear cell sarcoma of soft tissue (1/10, 0 diffuse), low-grade fibromyxoid sarcoma (1/5, 0 diffuse), Ewing sarcoma (2/10, 1 diffuse), CIC-rearranged sarcoma (8/8, 4 diffuse), BCOR-sarcoma (2/5, 1 diffuse), melanoma (20/20, 14 diffuse), and thoracic SMARCA4-deficient undifferentiated tumor (5/5, all diffuse). All tested cases of spindle cell lipoma, dedifferentiated/pleomorphic liposarcoma, dermatofibrosarcoma protuberans, solitary fibrous tumor, inflammatory myofibroblastic tumor, myxoinflammatory fibroblastic sarcoma, nodular fasciitis, myxofibrosarcoma, epithelioid hemangioendothelioma, atypical vascular lesion, hemangioma, lymphangioma, vascular malformation, papillary endothelial hyperplasia, GIST, gastrointestinal clear-cell sarcoma, malignant melanotic nerve sheath tumor, neurofibroma, schwannoma, granular cell tumor, alveolar soft part sarcoma, epithelioid sarcoma, extraskeletal myxoid chondrosarcoma, myoepithelioma, ossifying fibromyxoid tumor, angiomatoid fibrous histiocytoma, PEComa, dermatofibroma, pleomorphic dermal sarcoma, and chordoma were negative. PRAME shows imperfect specificity in soft-tissue pathology but may serve as a diagnostic adjunct in selected differential diagnoses that show contrasting expression patterns.
Expression of P27~(kipl) ,SC3A,ER and PR in Endometrial Carcinoma and Their Significances

Xiaoyan Zhang

2005-01-01

Abstract:Objective: To study the expression of four tumor markers SC3A,P27 kipl ,estrogen receptor(ER) and progestogen receptor (PR) in endometrial carcinoma and their significances.Method: Expressions of SC3A and P27 kipl were detected by using immunohistochemical method in 66 cases with endometrial carcinoma,29cases with non-typical endometrial hyperplasia and 31 cases with normal endometrial tissues and expressions of ER and PR were detected in 66 cases with endometrial carcinoma. Results: In endometrial carcinoma,non-typical endometrial hyperplasia and normal endometrial tissues,the positive rates were 81.8%,51.7%and 12.9% respectivly.The positive rates of P27 kipl were 53.0%,75.8%and 87.1% respectively.The results showed that the positive rates of both SC3A and P27 kipl have a significant difference compared with control group (P0.05 and P0.01). The positive rates of ER and PR in 66 cases with endometrial carcinoma were 56.0% and 53.0% (P0.05). There were no difference for the positive rates of SC3A in different differentiation degree of endometrial carcinoma,while the positive rates of P27 kipl were decreased following the rising degree of malignancy of the carcinoma. Conclusion: Detection of SC3A has a practical significance for the early discovery of endometrial carcinoma and improvement of detective rates. Detection of SC3A has a practical significance for the early discovery of endometrial carcinoma and improvement of detective rates.Detection of P27 kipl ,ER and PR is a valuable index for the choice of appropriate therapy program in clinical treatment and prediction of prognosis.

Localization of the activity of arylsulphatases A and B in the rat salivary glands.

Performance of preferentially expressed antigen in melanoma (PRAME) immunohistochemistry for metastatic melanoma in cytology specimens

PRAME Expression Is a Useful Tool in the Diagnosis of Primary and Metastatic Dedifferentiated and Undifferentiated Melanoma

PRAME expression in spindle cell melanoma, malignant peripheral nerve sheath tumour, and other cutaneous sarcomatoid neoplasms: a comparative analysis

Analysis of PRAME immunocytochemistry in 109 acral malignant melanoma in situ

Preferentially Expressed Antigen in Melanoma Immunohistochemistry As an Adjunct for Differential Diagnosis in Acral Lentiginous Melanoma and Acral Nevi

Differential expression of preferentially expressed antigen in melanoma (PRAME) in testicular germ cell tumors - A comparative study with SOX17

Comparison of S100A8 and PRAME as biomarkers for distinguishing melanoma from melanocytic nevus: a case-control analysis

A Comparison of Preferentially Expressed Antigen in Melanoma Immunohistochemistry and Diagnostic Gene Expression-Profiling Assay in Challenging Melanocytic Proliferations

PRAME Expression in Challenging Dermal Melanocytic Neoplasms and Soft Tissue Tumors With Melanocytic Differentiation

Progesterone Receptor and Progesterone Receptor B Isoform Expression and Their Clinical Significance in Endometrial Adenocarcinoma

Clinical implication of PRAME immunohistochemistry in differentiating melanoma in situ and dysplastic nevus in non‐acral nevus‐associated melanoma in situ: An institutional experience and meta‐analysis

PRAME expression and its prognostic significance in invasive breast carcinoma

Evaluation of PRAME immunohistochemistry in cutaneous vascular neoplasms reveals frequent expression in primary and post‐irradiation cutaneous angiosarcomas

Endocervical adenocarcinomas classified by International Endocervical Adenocarcinoma Criteria and Classification: a clinicopathological and prognostic analysis of 286 cases

Relationships Between the Molecular Biomarkers and the Clinicopathologic Features and Prognosis in Endometrial Carcinoma

Distinctive Features of Immunostaining and Mutational Load in Primary Pulmonary Enteric Adenocarcinoma: Implications for Differential Diagnosis and Immunotherapy

The synergistic effect of conventional and sustained delivery of antioxidants on LNCaP prostate cancer cell line.

PRAME Is an Effective Tool for the Diagnosis of Nevus-Associated Cutaneous Melanoma

PRAME immunohistochemistry in soft tissue tumors and mimics: a study of 350 cases highlighting its imperfect specificity but potentially useful diagnostic applications

Expression of P27~(kipl) ,SC3A,ER and PR in Endometrial Carcinoma and Their Significances